Phase II Clinical Trial of Axitinib (AG-013736) for Patients with Pheochromocytoma and Paraganglioma

Share

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Columbia University / Pfizer
ClinicalTrials.gov Identifier: NCT03839498
Axitinib PubChem CID: 6450551

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center [Photo: National Cancer Institute]
Investigators at Columbia University Medical Center have opened a Phase I clinical trial to determine the activity of axitinib (INLYTA®, Pfizer) as a single agent in tumor and hormonal responses in malignant pheochromocytoma/paraganglioma.

See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.

Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.




The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA image
*

This site uses Akismet to reduce spam. Learn how your comment data is processed.